Compare Novartis AG (NVS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs State Street SPDR S&P Homebuilders ETF — how do they compare? Novartis AG trades at $139.46 (market cap $262.64B), while State Street SPDR S&P Homebuilders ETF trades at $99.14. The key difference: Novartis AG pays a 3.44% dividend while State Street SPDR S&P Homebuilders ETF pays none, and Novartis AG is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| NVS | XHB | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $121.36 |
52-Week Low | $121.80 | $94.86 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
XHB trades at $100.75, down 2.42% today amid bearish technical signals. The ETF shows neutral oscillators but bearish moving averages, with support at $98-$100 and resistance at $102-$105. Recent housing data shows mixed signals with new home sales rising 1.6% in June (Census Bureau, June 2026) while existing home sales declined 2.4% (WSJ, July 9, 2026).
The homebuilding sector faces headwinds from high mortgage rates and record home prices, though institutional interest remains with Greenland Capital's $17.33 million investment (Defense World, September 7, 2026). Key catalysts include housing affordability legislation and potential market rebound opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
